It is a single-stock leveraged ETF designed to track the amplified daily performance of Eli Lilly common stock. Rather than broadly tracking a specific index, the exposure is built around the price movement of one company and the variables of the pharmaceutical industry.

It is suited for active investors who continuously monitor Eli Lilly's short-term price direction and understand the loss potential associated with leverage and daily rebalancing.

This is an actively managed ETF run by Direxion.

The following sentence contains no leaked Chinese characters and is already in pure natural English. No changes needed.

It is designed to follow the amplified daily return of Eli Lilly common stock and uses derivatives such as swaps to achieve the target exposure. The longer the holding period, the more the cumulative performance can diverge from a simple multiple of the underlying stock.

• Concentrated single-stock exposure
• Target exposure reset on every business day
• Leverage structure implemented through derivatives

Assets under management (AUM) stand at $20.0M, and the total expense ratio is 1.07% annually.

Because the structure resets its target exposure daily, investors should interpret not only trading costs and fees but also bid-ask spreads, liquidity, and changes in the underlying stock's volatility.

Performance can be highly sensitive to Eli Lilly's earnings expectations, pipeline progress, and news on drug pricing and regulation. Because of the leverage structure, even when the underlying stock moves in the same direction, the cumulative result can vary significantly depending on the path of volatility.

Fund flows for single-stock leveraged ETFs are sensitive to short-term expectations for a specific company and to market volatility. When trading activity concentrates in one direction, bid-ask spreads and transaction costs at the time of execution can affect realized performance, making liquidity monitoring essential.

While it allows investors to focus on the short-term directional view of the underlying stock, the combination of concentration and the daily compounding effect creates significant uncertainty in long-term performance. Key Strengths: - Direct Single-Stock Exposure: The structure responds intensely to Eli Lilly's price moves, clearly reflecting company-specific catalysts. - Daily Target Management: Target exposure is adjusted on each business day, providing a clear benchmark for short-term strategies. - Quarterly Distribution Structure: Distributions are made quarterly, but the level and nature of those payouts should be reviewed separately from investment returns. Things to Watch: - Concentration Risk: Exposure to a single company and pharmaceutical-industry variables makes the fund highly sensitive to company-specific earnings and regulatory changes. - Daily Rebalancing Effect: In sustained volatile environments, cumulative performance can diverge from the path of the underlying stock. - Amplified Leverage Losses: Adverse price moves can magnify losses, and principal loss is possible. - Liquidity Costs: Bid-ask spreads and transaction costs can arise on execution, so order types and fill conditions should be reviewed.

The TQQQ ETF shown in the comparison table provides daily leveraged exposure centered on large-cap growth stocks, while the SOXL ETF delivers exposure focused on the semiconductor industry, so its underlying asset scope differs from the ELIL ETF's single pharmaceutical concentration. The QLD ETF is structured to amplify exposure to large-cap Nasdaq growth stocks, and the SSO ETF and SPXL ETF are built on the moves of US large-cap equity indices, so investors should compare each one's diversification range, fee level, asset size, and volatility management approach. These products are less direct substitutes for the ELIL ETF than comparable leveraged vehicles with different use cases.

When reviewing the ELIL ETF, investors should look first at the fact that the leverage structure changes outcomes depending on holding period and the path of volatility, not just at the near-term price outlook for the underlying company. Before placing an order, it is worth checking liquidity, distribution history, and the method used to reset target exposure.

This product combines single-stock exposure with leverage, so even small moves in the underlying stock can be magnified substantially. If volatility persists or the direction shifts frequently, daily rebalancing and compounding effects can cause cumulative performance to deviate from expectations, and pharmaceutical regulation and pipeline news remain risk factors.

The ELIL ETF is best understood as a trading vehicle focused on Eli Lilly's short-term directional view. For any long-term holding decision, investors should comprehensively review leverage, daily rebalancing, trading costs, liquidity, and the nature of quarterly distributions alongside the underlying stock's own investment case.